Related Experiment Video
Updated: Jul 28, 2025
A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
Published on: December 23, 2016
Low-Generation Cationic Phosphorus Dendrimers: Novel Approach to Tackle Drug-Resistant
Evgeny Apartsin1,2,3, Abdul Akhir4, Grace Kaul4,5
1Laboratoire de Chimie de Coordination du CNRS, 205 Route de Narbonne, BP 44099, 31077 Toulouse Cedex 4, France.
Abstract:
The incessant, global increase in antimicrobial resistance (AMR) is a very big challenge for healthcare systems. AMR is predicted to grow at an alarming pace, with a dramatic increase in morbidity, mortality, and a 100 trillion US$ loss to the global economy by 2050. The mortality rate caused by methicillin-resistant S. aureus (MRSA) is much higher as compared to infections caused by drug-susceptible S. aureus. Additionally, there is a big paucity of therapeutics available for treatment of serious infections caused by MRSA. Thus, the discovery and development of novel therapies is an urgent, unmet medical need. In this context, we synthesized AE4G0, a low-generation cationic-phosphorus dendrimer expressing potent antimicrobial activity against S. aureus and Enterococcus sp., and demonstrating a broad selectivity index against eukaryotic cells. AE4G0 exhibits concentration-dependent, bactericidal activity and synergizes with gentamicin, especially against gentamicin-resistant MRSA NRS119. Fluorescence and scanning electron microscopy demonstrate that treatment with AE4G0 led to the utter destruction of S. aureus ATCC 29213 without inducing resistance, despite repeated exposure. When tested in vivo, AE4G0 demonstrates significant efficacy against S. aureus ATCC 29213, alone and in combination with gentamicin against gentamicin-resistant S. aureus NRS119 in the murine skin model of infection. Taken together, AE4G0 demonstrates the potential to be translated as a novel therapeutic option for the treatment of topical, drug-resistant S. aureus infections.
Insights
A novel cationic-phosphorus dendrimer, AE4G0, shows potent antimicrobial activity against drug-resistant bacteria like methicillin-resistant Staphylococcus aureus (MRSA). It effectively treats infections and synergizes with existing antibiotics, offering a promising new therapeutic option.
Area of Science:
- Microbiology
- Medicinal Chemistry
- Infectious Diseases
Background:
- Antimicrobial resistance (AMR) poses a significant global health threat, leading to increased morbidity, mortality, and economic losses.
- Methicillin-resistant Staphylococcus aureus (MRSA) infections have higher mortality rates and limited therapeutic options.
- Novel antimicrobial agents are urgently needed to combat drug-resistant bacterial infections.
Purpose of the Study:
- To synthesize and evaluate a novel cationic-phosphorus dendrimer, AE4G0, for its antimicrobial activity.
- To assess the efficacy of AE4G0 against Staphylococcus aureus and Enterococcus species, including resistant strains.
- To investigate the potential of AE4G0 as a therapeutic option for drug-resistant S. aureus infections.
Main Methods:
- Synthesis of AE4G0, a low-generation cationic-phosphorus dendrimer.
- In vitro antimicrobial susceptibility testing against S. aureus and Enterococcus sp.
- Microscopy (fluorescence and scanning electron) to visualize bacterial destruction.
- In vivo efficacy testing in a murine skin infection model.
- Synergy testing with gentamicin against resistant MRSA strains.
Main Results:
- AE4G0 demonstrated potent, concentration-dependent bactericidal activity against S. aureus and Enterococcus sp.
- AE4G0 showed broad selectivity against eukaryotic cells.
- Microscopy confirmed AE4G0 induced complete destruction of S. aureus without resistance development upon repeated exposure.
- AE4G0 exhibited significant efficacy in vivo, both alone and in combination with gentamicin against resistant MRSA.
- Synergistic activity was observed between AE4G0 and gentamicin against gentamicin-resistant MRSA.
Conclusions:
- AE4G0 is a promising novel antimicrobial agent with potent activity against drug-resistant S. aureus.
- The dendrimer AE4G0 demonstrates efficacy in preclinical models and potential for treating topical, resistant S. aureus infections.
- AE4G0 represents a potential new therapeutic strategy to address the challenge of antimicrobial resistance.
Related Concept Videos
01:17Pore Transport and Ion-Pair Transport
Pore transport, also known as convective transport, is a process where small molecules like urea, water, and sugars rapidly cross cell membranes as though there were channels or pores in the membrane. Although direct microscopic evidence is limited but the concept of pores or channels is widely accepted based on physiological evidence. Despite the lack of direct...
02:56Treatment Resistant Cancers
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...